HCC surveillance is recommended every six months in high-risk patients—such as those with cirrhosis of any etiology or chronic HBV infection—using ultrasound in combination with alpha-fetoprotein (AFP), which increases sensitivity for early detection from 45% to 63% [2]. The gene discussed is AFP; the disease is Cirrhosis.